Bicyclo Ring System Having The Seven-membered Hetero Ring As One Of The Cyclos Patents (Class 514/221)
  • Patent number: 11492340
    Abstract: Disclosed herein are compounds, compositions, and methods for reactivating or realkylating aged acetylcholinesterase inhibited by or conjugated to the organophosphorus compound. The organophosphorus compound can be a nerve agent. The acetylcholinesterase can be in the central nerve system (CNS) and/or the peripheral nervous system (PNS) of a subject. Accordingly, methods for ameliorating, diminishing, reversing, treating or preventing the toxic effects of an organophosphorus compound in a subject are provided herein. Methods for prophylactic or therapeutic treatment of exposure to an organophosphorus nerve agent are also provided.
    Type: Grant
    Filed: February 15, 2018
    Date of Patent: November 8, 2022
    Assignee: OHIO STATE INNOVATION FOUNDATION
    Inventors: Christopher Hadad, Christopher Callam, Jeremy Beck, Qinggeng Zhuang, Andrew Franjesevic, Thomas Corrigan, Craig McElroy
  • Patent number: 11446276
    Abstract: Alzheimer's disease is treated using THC (alone, or in combination with melatonin) administered in an ultra-low dose amount sufficient to (i) reduce A? protein levels; (ii) reduce A? aggregation: (iii) maintain A?PP protein levels; (iv) enhance mitochondrial functioning; (v) decrease phosphorylation of GSK-3? protein; (vi) decrease GSK-3? protein levels; (vii) decrease phosphorylation of Tau protein; and/or (viii) maintain Tau protein levels, in said patient without severe psychological impairments and side effects associated with higher doses of THC.
    Type: Grant
    Filed: January 9, 2020
    Date of Patent: September 20, 2022
    Assignee: University of South Florida
    Inventor: Chuanhai Cao
  • Patent number: 11382889
    Abstract: Therapeutic solutions for axonal degeneration include use of NRF2 activators in prevention and/or treatment of axonal degeneration. A method of prevention and/or treating axonal degeneration includes administering a therapeutically effective amount of a NRF2 activator selected from a GSK3 inhibitor or the compound of formula (I): wherein R1 and R2, which may be the same or different, independently represent H, a linear, branched wherein R1 and R2, which may be the same or different, independently represent a linear, branched or cyclic, saturated or unsaturated C1-6 alkyl radical, a pharmaceutical salt thereof or a metabolite or precursor of the dimethyl fumarate to a patient in need of the treatment.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: July 12, 2022
    Assignees: INSTITUT D'INVESTIGACIÓ BIOMÈDICA DE BELLVITGE (IDIBELL), INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS
    Inventors: Aurora Pujol Onofre, Stéphane Fourcade
  • Patent number: 11344569
    Abstract: The invention relates to compositions and methods of treating a sleep-wake disorder or neurodegenerative diseases using modified resistant maltodextrin.
    Type: Grant
    Filed: November 14, 2018
    Date of Patent: May 31, 2022
    Assignee: Northwestern University
    Inventors: Kazuhiro Shimomura, Martha Hotz Vitaterna, Phyllis C. Zee
  • Patent number: 11344559
    Abstract: The present disclosure relates to PI3K? inhibitors and methods of their use.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: May 31, 2022
    Assignee: The Regents of the University of California
    Inventors: Judith Varner, Rommie Amaro, Megan Kaneda, Robert Malmstrom, Victoria Feher
  • Patent number: 11344627
    Abstract: Described herein are hybrid nanoparticles that are exosomes loaded with one or more nanoparticle dendrimers. Also included are pharmaceutical compositions including the hybrid nanoparticles and methods of making the hybrid nanoparticles. Also described is a method of treating a human subject by administering to the human subject the above-described hybrid nanoparticles.
    Type: Grant
    Filed: June 19, 2018
    Date of Patent: May 31, 2022
    Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Seungpyo Hong, Sin-Jung Park
  • Patent number: 11278551
    Abstract: Provided herein are methods for treating a cholecystokinin (CCK) receptor-expressing cancerous tumor in a subject. The methods comprising administering to the subject an effective amount of a CCK receptor inhibitor and an effective amount of an immune checkpoint inhibitor, wherein the CCK receptor inhibitor inhibits one or more CCK receptors selected from the group consisting of a CCK-A receptor, a CCK-B receptor and a CCK-C receptor, and wherein the immune checkpoint inhibitor is a programmed cell death protein 1 (PD1) inhibitor or a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) inhibitor.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: March 22, 2022
    Assignee: GEORGETOWN UNIVERSITY
    Inventors: Jill P. Smith, Louis Weiner, Sandra Jablonski, Sandeep Nadella, Shangzi Wang
  • Patent number: 11278525
    Abstract: A SIRT6 activating molecule as shown in Tables 1-3 and 9, or a compound according to a pharmacophore as described herein.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: March 22, 2022
    Assignee: SirTLab Corporation
    Inventors: Haim Yosef Cohen, Yariv Kanfi
  • Patent number: 11247973
    Abstract: The invention relates to compounds of formula (I), and pharmaceutical uses thereof. Particular aspects of the invention relate to methods of synthesising the compounds and the use of those compounds in treating, ameliorating, or preventing a microbial infection.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: February 15, 2022
    Assignee: The University of Durham
    Inventor: Stuart Cockerill
  • Patent number: 11241383
    Abstract: Alprazolam formulated as an inhaled condensation aerosol and method for treating epilepsy and/or seizures.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: February 8, 2022
    Assignee: ALEXZA PHARMACEUTICALS, INC.
    Inventors: James Cassella, Lily Gong, Edwin S. Kamemoto
  • Patent number: 11236085
    Abstract: Compounds and methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
    Type: Grant
    Filed: October 22, 2019
    Date of Patent: February 1, 2022
    Assignee: Gilead Sciences, Inc.
    Inventors: Zhimin Du, Michael Graupe, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Eric Q. Parkhill, Barton W. Phillips, Scott P. Simonovich, Peiyuan Wang, Jie Xu, Christopher A. Ziebenhaus
  • Patent number: 11161825
    Abstract: The present invention covers 4-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-7-carboxamide compounds of general formula (I): in which R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, R5 and X are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: August 9, 2018
    Date of Patent: November 2, 2021
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft
    Inventors: Jörg Weiske, Carlo Stresemann, Stefan Nikolaus Gradl, Ulrike Röhn, Clara Christ, Holger Steuber, Manfred Husemann, Norbert Schmees, Kai Thede, Stephan Siegel, Antonius Ter Laak
  • Patent number: 11155556
    Abstract: The present invention relates to use of pyrimido-diazepinone compounds that are able to modulate protein kinases such as PI3K-? and PI3K-?, which are members of the Class I Type IA and Class I Type IB family of phosphatidylinositol-4,5-bisphosphate 3-kinases, and the use of such compounds in the treatment of various diseases, disorders or conditions.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: October 26, 2021
    Assignee: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Nathanael S. Gray, Tinghu Zhang, Fleur M. Ferguson, Jean Zhao, Jing Ni
  • Patent number: 11135206
    Abstract: The present invention provides novel pyrazolo[4,3-c]quinoline derivatives exhibiting specifically inhibition activity to microbiota ?-glucuronidase, whereby providing potent activities to prevent chemotherapy-induced diarrhea (CID) of cancers. Therefore, the compounds of the present invention can be used as (1) chemotherapy-adjuvant to prevent chemotherapy-induced diarrhea (CID) and enhance chemotherapeutic efficiency of cancers; (2) health-food supplement to prevent the carcinogens induced colon carcinoma.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: October 5, 2021
    Assignee: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Yeh-Long Chen, Tian-Lu Cheng, Cherng-Chyi Tzeng, Chih-Hua Tseng, Ta-Chun Cheng, Kai-Wen Cheng, Wei-Fen Luo
  • Patent number: 11090288
    Abstract: The present disclosure relates to a compound of formula or a pharmaceutically acceptable salt thereof; wherein U, R1, R2, R3 and Q are as defined herein. The disclosure also provides a method for treating or preventing a method for the prevention, treatment and/or alleviation of one or more autoimmune or alloimmune disease, pharmaceutical compositions and combination comprising a therapeutically effective amount of a compound, as defined herein.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: August 17, 2021
    Assignees: UNIVERSITY HEALTH NETWORK, CANADIAN BLOOD SERVICES
    Inventors: Donald R. Branch, Lakshmi P. Kotra
  • Patent number: 11071720
    Abstract: The present invention relates to the treatment of mixed lineage leukemia. In particular, the present invention relates to therapies involving the induction of proteolysis of the MLL fusion proteins that result from the chromosomal translocations affecting the MLL gene at 11q23.
    Type: Grant
    Filed: November 2, 2017
    Date of Patent: July 27, 2021
    Assignee: UCL BUSINESS LTD
    Inventors: Jasper De Boer, Sandra Cantilena
  • Patent number: 11052072
    Abstract: The present invention provides novel pyrazolo[4,3-c]quinoline derivatives exhibiting specifically inhibition activity to microbiota ?-glucuronidase, whereby providing potent activities to prevent chemotherapy-induced diarrhea (CID) of cancers. Therefore, the compounds of the present invention can be used as (1) chemotherapy-adjuvant to prevent chemotherapy-induced diarrhea (CID) and enhance chemotherapeutic efficiency of cancers; (2) health-food supplement to prevent the carcinogens induced colon carcinoma.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: July 6, 2021
    Assignee: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Yeh-Long Chen, Tian-Lu Cheng, Cherng-Chyi Tzeng, Chih-Hua Tseng, Ta-Chun Cheng, Kai-Wen Cheng, Wei-Fen Luo
  • Patent number: 11045462
    Abstract: Described are methods of treating or reducing the toxic effects of exposure to a nerve agent, comprising administering to a subject in need thereof (i) an AMPA/GluR5(GluK1) kainate receptor antagonist (such as LY293558) and (ii) an NMD A receptor antagonist (such as an antimuscarinic compound, such as caramiphen), as well as methods of treating, reducing the risks of, or preventing a neurological condition such as epilepsy, seizures, post-traumatic stress disorder, status epilepticus, depression, or anxiety, comprising administering to a subject in need thereof (i) an AMPA/GluR5(GluK1) kainate receptor antagonist (such as LY293558) and (ii) an NMDA receptor antagonist (such as an antimuscarinic compound, such as caramiphen). The methods may further comprise administering a positive allosteric modulator of synaptic GABAA receptors, such as a benzodiazepine, such as midazolam, to the subject. The methods are suitable for use in children and adults. Related compositions and uses also are described.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: June 29, 2021
    Assignee: THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC.
    Inventors: Maria F. Braga, Vassiliki Aroniadou-Anderjaska
  • Patent number: 11008325
    Abstract: Provided herein are, inter alia, compositions that bind to a PDZ1 domain of MDA-9/Syntenin (syndecan binding protein: SDCBP), thereby inhibiting MDA-9/Syntenin activity, and methods of use of same. The compositions and methods provided herein are useful for treating cancer and preventing cancer metastasis, particularly in cancers that have increased MDA-9/Syntenin expression.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: May 18, 2021
    Assignees: VIRGINIA COMMONWEALTH UNIVERSITY, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Paul B. Fisher, Maurizio Pellecchia, Swadesh K. Das, Timothy P. Kegelman, Bainan Wu, Surya K. De, Jun Wei, Mitchell E. Menezes, Luni Emdad
  • Patent number: 10975093
    Abstract: The present disclosure provides compounds represented by Formula I: I, and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R1, R2a, R2b, R3, R4, Ar, L, X, Y, and B are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to degradation of BET bromodomains such as cancer.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: April 13, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Yang Hu, Chong Qin, Fuming Xu, Jiantao Hu, Weiguo Xiang, Bing Zhou
  • Patent number: 10886370
    Abstract: A silicon carbide body includes a drift structure having a first conductivity type, a body region, and a shielding region. The body and shielding regions, of a second conductivity type, are located between the drift structure and a first surface of the silicon carbide body. First and second trench gate stripes extend into the silicon carbide body. The body region is in contact with a first sidewall of the first trench gate stripe. The shielding region is in contact with a second sidewall of the second trench gate stripe. The second sidewall has a first length in a lateral first direction parallel to the first surface. A supplementary region of the first conductivity type contacts one or more interface areas of the second sidewall. The one or more interface areas have a combined second length along the first direction, the second length being at most 40% of the first length.
    Type: Grant
    Filed: October 31, 2019
    Date of Patent: January 5, 2021
    Assignee: Infineon Technologies AG
    Inventors: Florian Grasse, Axel Sascha Baier, Wolfgang Bergner, Barbara Englert, Christian Strenger
  • Patent number: 10806722
    Abstract: The subject invention describes a method of use of Ropinirole™ to alleviate and control menopausal symptoms in women, and in particular, hot flashes. The invention describes the use of Ropinirole as a dopamine agonist with affinity for the dopamine D2, D3, or D4 receptors. Ropinirole may also be used to treat menopausal symptoms in conjunction with Tizanidine™ to further reduce the effects menopausal symptoms by providing a sedative and muscle relaxant effect which aids in sleep. The combination of Ropinirole and Tizanidine provides a useful new compound for treatment of menopausal symptoms that are most disruptive to the functioning in activities of daily living.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: October 20, 2020
    Inventor: Robert L. Knobler
  • Patent number: 10793515
    Abstract: A series of novel amides showing broad pharmaceutical activity. Compounds described herein are effective as anticonvulsants, chemical countermeasures, and analgesics. Such compounds also show, neuroprotective/neuroreparative effects and activity against spinal muscular atrophy. Such pharmaceutically active compounds show utility in the treatment of central nervous system (“CNS”) diseases and disorders, such as anxiety, depression, insomnia, migraine headaches, schizophrenia, neurodegenerative diseases (e.g., Parkinson's disease, Alzheimer's, ALS, and Huntington's disease) spasticity, and bipolar disorder. Furthermore, such compounds may additionally find utility as analgesics (e.g., for the treatment of chronic or neuropathic pain) and as neuroprotective agents useful in the treatment of stroke(s), and/or traumatic brain and/or spinal cord injuries.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: October 6, 2020
    Assignee: AURIMMED PHARMA, INC.
    Inventors: Amir Pesyan, Manuel F. Balandrin
  • Patent number: 10786580
    Abstract: Compounds are described herein where CCK2R targeting ligands are attached to an imaging agent through a linker. The compounds can be used in the detection, diagnosis, imaging and treatment of cancer.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: September 29, 2020
    Assignee: On Target Laboratories, LLC
    Inventors: Sumith A. Kularatne, Pravin Gagare, Mohammad Noshi
  • Patent number: 10780095
    Abstract: In alternative embodiments, provided are methods for: modifying circadian rhythmicity or timing in a mammal, treating psychiatric conditions or symptoms due to alterations in a human circadian regulatory system, treating sleep problems in a mammal, or inducing sleep or activity suppression, or causing an arousal or wakening reaction, comprising administration to a mammal or human a compound or composition capable of modifying a prokineticin 2 (PK2) expression or activity, and/or a PKR2 (PK2 receptor), a vasopressin receptor (VR), and/or a melatonin receptor (MR) expression or activity.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: September 22, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Qun-Yong Zhou
  • Patent number: 10765666
    Abstract: Treatment of Tourette syndrome using gaboxadol or a pharmaceutically acceptable salt thereof is provided. Treatment of tics using gaboxadol or a pharmaceutically acceptable salt thereof is provided. Treatment of stuttering using gaboxadol or a pharmaceutically acceptable salt thereof is provided. Therapeutic compositions that may be used to improve one or more symptoms of Tourette syndrome are provided. Therapeutic compositions that may be used to improve one or more symptoms of tics are provided. Also provided are therapeutic compositions that may be used to improve one or more symptoms of stuttering.
    Type: Grant
    Filed: September 20, 2019
    Date of Patent: September 8, 2020
    Assignee: OVID THERAPEUTICS INC
    Inventor: Matthew During
  • Patent number: 10765751
    Abstract: A method for treating tumor or inflammation in a patient in need thereof by administering a pH sensitive drug which includes a pH sensitive carrier including at least one amphipathic substance, and a physiologically active substance supported in the pH sensitive carrier to induce the pH sensitive carrier to develop a membrane disruptive function and to deliver the physiologically active substance to the site.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: September 8, 2020
    Assignee: TERUMO KABUSHIKI KAISHA
    Inventor: Naoki Sakaguchi
  • Patent number: 10752598
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: August 25, 2020
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Yat Sun Or, Thomas P. Blaisdell, Brian C. Shook, In Jong Kim
  • Patent number: 10702537
    Abstract: A method of treating a condition of in a human patient comprising pharmacologically activating a translocator protein of 18 kDa (TSPO), wherein the condition is one of a chronic methamphetamine addiction, a medical consequence of methamphetamine use; a behavioral consequence of methamphetamine use, an HIV associated cognitive motor disorder, an HIV-associated neurodegenerative disorder, and a neuroinflammatory response.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: July 7, 2020
    Assignee: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY and Agricultural and Mechanical College
    Inventors: Nicholas E. Goeders, Christopher Dalton Schmoutz
  • Patent number: 10669242
    Abstract: The present invention relates to benzodiazepine derivative compounds of formula (I), or pharmaceutically acceptable salts thereof. The present benzodiazepine compounds are useful Clostridium difficile inhibitors in the treatment of Clostridium difficile infection in humans. The present invention provides a pharmaceutical composition containing benzodiazepine compounds of formula (I) and a method of making as well as a method of using the same in treating patients infected with Clostridium difficile infection by administering the same. The compounds of the present invention may be used in combination with additional antibiotics or anti-toxin antibody drugs.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: June 2, 2020
    Assignee: Venenum Biodesign, LLC
    Inventors: Jeffrey J. Letourneau, Andrew G. Cole, Brett A. Marinelli, Jorge G. Quintero
  • Patent number: 10604523
    Abstract: The present invention relates to novel 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives as inhibitors of phosphodiesterase 2 (PDE2) and to a lesser extent of phosphodiesterase 10 (PDE10) or as inhibitors of both, phosphodiesterases 2 and 10. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which PDE2 is involved, or disorders in which both PDE2 and PDE10 are involved, such as neurological and psychiatric disorders, and endocrinological or metabolic diseases. The present invention also relates to radiolabelled compounds which may be useful for imaging and quantifying the PDE2 enzyme in tissues, using positron-emission tomography (PET).
    Type: Grant
    Filed: June 26, 2012
    Date of Patent: March 31, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: José Ignacio Andrés-Gil, Peter Jacobus Johannes Antonius Buijnsters, Andrés Avelino Trabanco-Suárez, Meri De Angelis, Greta Constantia Peter Vanhoof, Jérôme Emile Georges Guillemont, Frederik Jan Rita Rombouts, Maarten Vliegen, Guy Maurits R. Bormans, Sofie Jeanne Leopoldine Celen
  • Patent number: 10597367
    Abstract: Provided herein are small molecule active metabotropic glutamate subtype-2 and -3 receptor negative allosteric modulators (NAMs), compositions comprising the compounds, and methods of using the compounds and compositions.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: March 24, 2020
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Nicholas David Peter Cosford, Dhanya Raveendra-Panickar, Douglas J. Sheffler, John Howard Hutchinson, Reto Andreas Gadient
  • Patent number: 10561668
    Abstract: A method of treating a condition of in a human patient comprising pharmacologically activating a translocator protein of 18 kDa (TSPO), wherein the condition is one of a chronic methamphetamine addiction, a medical consequence of methamphetamine use; a behavioral consequence of methamphetamine use, an HIV associated cognitive motor disorder, an HIV-associated neurodegenerative disorder, and a neuroinflammatory response.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: February 18, 2020
    Assignee: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY
    Inventors: Nicholas E. Goeders, Christopher Dalton Schmoutz
  • Patent number: 10548846
    Abstract: A solid oral dosage form is provided, comprising a compound of Formula I or a pharmaceutically acceptable salt thereof, tenofovir alafenamide or a pharmaceutically acceptable salt thereof, and emtricitabine or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: February 4, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Benjamin Micah Collman, Lei Hong, Joanna M. Koziara
  • Patent number: 10501481
    Abstract: The present invention relates to heterocyclic compounds, their process of preparation, pharmaceutical compositions comprising these compounds and use thereof, optionally in combination with other antibacterial agents and/or beta-lactam compounds, for the prevention or treatment of bacterial infections. The present invention also relates to the use of these compounds as ?-lactamase inhibitors and/or as antibacterial agents.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: December 10, 2019
    Assignee: MUTABILIS
    Inventors: Julie Brias, Sophie Chasset, Francis Chevreuil, Nicolas Lecointe, Benôit Ledoussal, Frédéric Le Strat, Sophie Vomscheid, Sébastien Richard, Fabien Faivre, Julien Barbion, Audrey Caravano, Géraldine Le Fralliec, Christophe Simon
  • Patent number: 10501424
    Abstract: The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: December 10, 2019
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Bingsong Han, Jennifer R. Thomason, Mary-Margaret Zablocki, Cuixian Liu, Aleksandra Rudnitskaya, David R. Lancia, Jr., David S. Millan, Matthew W. Martin
  • Patent number: 10494354
    Abstract: The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: December 3, 2019
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Bingsong Han, Jennifer R. Thomason, Mary-Margaret Zablocki, Cuixian Liu, Aleksandra Rudnitskaya, David R. Lancia, Jr., David S. Millan, Matthew W. Martin
  • Patent number: 10494353
    Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: December 3, 2019
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Bingsong Han, Jennifer R. Thomason, Mary-Margaret Zablocki, Cuixian Liu, Aleksandra Rudnitskaya, David R. Lancia, Jr., David S. Millan, Matthew W. Martin
  • Patent number: 10478408
    Abstract: A method of reducing the risk of medication-related overdose, death, or other injury associated with inappropriate consumption of alcohol in conjunction with prescription opioid analgesics, comprising: administering a combination medication having an effective amount of one or more opioid medications, and an effective amount of one or more aldehyde dehydrogenase inhibitors, in order to provide the powerful analgesic effects of the opioid in conjunction with a substance that prevents concomitant alcohol consumption, thereby reducing the risk of alcohol mediated opioid overdose or death. A combination medication, including an effective amount of one or more opioid medications, and an effective amount of one or more aldehyde dehydrogenase inhibitors and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: November 19, 2019
    Inventor: Michael Presti
  • Patent number: 10472337
    Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: November 12, 2019
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Bingsong Han, Jennifer R. Thomason, Mary-Margaret Zablocki, Cuixian Liu, Aleksandra Rudnitskaya, David R. Lancia, Jr., David S. Millan, Matthew W. Martin
  • Patent number: 10464910
    Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: November 5, 2019
    Assignee: Forma Therapeutics, Inc.
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Bingsong Han, Jennifer R. Thomason, Mary-Margaret Zablocki, Cuixian Liu, Heather Davis, Aleksandra Rudnitskaya, David R. Lancia, Jr., Kenneth W. Bair, David S. Millan, Matthew W. Martin
  • Patent number: 10457652
    Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: October 29, 2019
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Bingsong Han, Jennifer R. Thomason, Mary-Margaret Zablocki, Cuixian Liu, Heather Davis, Aleksandra Rudnitskaya, David R. Lancia, Jr., Kenneth W. Bair, David S. Millan, Matthew W. Martin
  • Patent number: 10426786
    Abstract: Provided are compositions comprising a benzodiazepine and a neurosteroid, containing one or both of the benzodiazepine and the neurosteroid in a subtherapeutic dose, and administration of such compositions for mitigation of an epileptic seizure. Further provided are compositions comprising a benzodiazepine, a neurosteroid, and an NMDA blocker, and administration of such compositions for mitigation of an epileptic seizure.
    Type: Grant
    Filed: July 13, 2017
    Date of Patent: October 1, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Michael A. Rogawski, Isaac N. Pessah, Zhengyu Cao, Pamela J. Lein
  • Patent number: 10421731
    Abstract: The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: where R, L, X1, X2, X3, X4, Y1, Y2, Y3, and Y4 are described herein.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: September 24, 2019
    Assignee: Forma Therapeutics, Inc.
    Inventors: Xiaozhang Zheng, Pui Yee Ng, Bingsong Han, Jennifer R. Thomason, Mary-Margaret Zablocki, Cuixian Liu, Aleksandra Rudnitskaya, David R. Lancia, Jr., David S. Millan, Matthew W. Martin, Kenneth W. Bair
  • Patent number: 10398706
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: These compounds are useful for treating Respiratory Syncytial Virus (RSV) infection. The present invention further relates to pharmaceutical compositions comprising these compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the invention.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: September 3, 2019
    Assignee: Enanta Pharmaceuticals, Inc.
    Inventors: Brian C. Shook, In Jong Kim, Jianming Yu, Thomas P. Blaisdell, Joseph Panarese, Yat Sun Or
  • Patent number: 10272077
    Abstract: The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: April 30, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Ian M. Bell, Mark E. Fraley, Steven N. Gallicchio, Anthony Ginetti, Helen J. Mitchell, Daniel V. Paone, Donnette D. Staas, Cheng Wang, C. Blair Zartman
  • Patent number: 10272061
    Abstract: The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and/or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: April 30, 2019
    Assignee: ALLERGAN SALES, LLC
    Inventors: Charles D. Ebert, Steven W. Sanders
  • Patent number: 10225017
    Abstract: To improve the signal quality of the optical signal emitted by a reconfigurable transmitter after a reconfiguration event, an optical transmitter includes a modulator, a digital signal processor, and a controller. The modulator is for modulating light by a driving signal with a reconfigurable format. The digital signal processor is for processing digital data to be transmitted by using parameters in order to generate the driving signal. The controller is for controlling the digital signal processor changing the parameters so as to keep the driving signal stable before and after changing the reconfigurable format.
    Type: Grant
    Filed: April 15, 2014
    Date of Patent: March 5, 2019
    Assignee: NEC CORPORATION
    Inventor: Emmanuel Le Taillandier De Gabory
  • Patent number: 10206931
    Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: February 19, 2019
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: F. Anthony Romero, Steven R. Magnuson, Richard Pastor, Vickie Hsiao-Wei Tsui, Jeremy Murray, Terry Crawford, Daniel J. Burdick, Brian K. Albrecht, Alexandre Cote, Alexander M. Taylor, Christopher G. Nasveschuck, Yves LeBlanc, Michael Charles Hewitt, Kwong Wah Lai, Kevin Chen
  • Patent number: 10047075
    Abstract: The present disclosure provides pyridines and pyrimidines of Formula I and pharmaceutically acceptable salts and solvates thereof: wherein A, G, W1, W2, W3, and R5 are defined as set forth in the specification. The present disclosure also provides uses of the compounds of Formula I and pharmaceutically acceptable salts and solvates thereof. In certain embodiments, Compounds of the present disclosure are useful for treating pain. In another embodiment, Compounds of the present disclosure are useful for treating a disorder responsive to blockade of sodium channels, or alleviating symptoms of the disorder.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: August 14, 2018
    Assignee: Purdue Pharma L.P.
    Inventor: Stephen M. Lynch